Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists

October 24, 2025 updated by: Goldman, Butterwick, Fitzpatrick and Groff

Prospective, Single Center, Open-label Study Assessing Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality and Biomarkers in Patients on Glucagon-like Peptide-1 Agonists

Clinical trial to assess the effect of microdroplet hyaluronic acid filler to the cheek skin (SKINVIVE™, JUVÉDERM®, Irvine, CA) on skin quality in patients undergoing medical weight loss with GLP-1 therapy.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

24 patients total (16 GLP1 and 8 non-GLP1) will receive one treatment with microdroplet hyaluronic acid filler (SKINVIVE™, JUVÉDERM®, Irvine, CA) to the cheeks, either at the beginning of the study or at the end. Patients will return for follow up visits at day 30, day 60 and and day 70, where they will undergo standardized 2D photography, VISIA photography and assessments.

Study Type

Interventional

Enrollment (Estimated)

24

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Adult women aged 25-50 years.
  2. Fitzpatrick skin types I-VI.
  3. Current treatment with a stable dose of GLP-1 agonist medication for at least the last 6 months, for 16 of the enrolled subjects. Remaining 8 subjects should not be taking or have a history of taking a GLP-1 agonist therapy in the last year.
  4. Presence of moderate skin changes (as defined by Modified Griffiths' Scale, with an average score of 4-6) in the following criteria: skin radiance/brightness, skin elasticity, tone evenness, skin firmness, fine lines, global wrinkles, and skin smoothness (tactile and visual).
  5. Participants must maintain a stable weight, defined as no greater than a 10% weight change from screening/baseline and throughout the study.
  6. Participants must have a body mass index (BMI) of 27 or less.
  7. Must be willing to sign a photography release and ICF, and complete the entire course of the study.
  8. Participant must agree to maintaining the same skincare routine they are currently using throughout the study period.
  9. Subjects in good general health based on investigator's judgment and medical history.
  10. Negative urine pregnancy test result at the time of study entry (if applicable).

  11. Females of childbearing potential must be willing to use an acceptable method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.

    1. 1. Acceptable methods of birth control are: oral contraceptive pill, injections, implants, patches, vaginal rings, intrauterine device/coil, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and/or vasectomized partner must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.
    2. 2. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months), without a uterus (hysterectomy) and/or both ovaries (oophorectomy), or bilateral tubal ligation.

Exclusion Criteria:

  1. The presence of severe facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 7-9) or minimal facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 0-3).
  2. Females who are pregnant, planning a pregnancy, or currently breast feeding during the study.
  3. Any uncontrolled systemic disease.
  4. History of autoimmune connective tissue disease.
  5. Current use of immunosuppressive medication.
  6. Weight change of greater than 10% during the study period.
  7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
  8. Active dermatitis (including but not limited to atopic dermatitis, psoriasis, rosacea, acne, melasma, etc.), active infections, or other skin condition in the proposed treatment area that in the investigator's opinion might interfere with the evaluation of study parameters.
  9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment. Botulinum toxin injections (Botox, Dysport, Xeomin, Daxify, Jeuveau) during the 6-month period before study treatment.
  10. Any investigational treatment for skin quality of the cheeks during the 12-month period before the study treatment.
  11. Creams/cosmeceuticals and/or home therapies for the prevention or treatment of skin fine lines, wrinkles, radiance, elasticity, firmness, or smoothness in the treatment area during the 4-week period before study treatment and throughout the course of the study.
  12. Subjects with scarring in the treatment areas. Subjects with a history of keloids will be excluded.
  13. Subjects who spray tanned or used sunless tanners in the treatment areas 4 weeks prior to study treatment.
  14. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and/or current pregnancy or breastfeeding.
  15. Inability to ambulate following the procedure.
  16. History of lidocaine and/or tetracaine sensitivity deemed by the investigator to preclude subject from enrolling into study.
  17. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.
  18. Subjects planning any cosmetic procedure to the treatment area during the study period, other than the treatment that will be performed by the investigator.
  19. Use of topical steroids, retinoids/retinols, or vitamin C to the face within the previous 2-weeks of screening.
  20. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: GLP1 Patients
16 participants who have been on a stable dose of GLP-1 agonist medication for at least the last 6 months will receive one treatment with microdroplet hyaluronic acid filler (SKINVIVE™, JUVÉDERM®, Irvine, CA) to the cheeks.
Device: Skinvive
16 GLP1 subjects treated with Skinvive to their cheeks for skin quality will be compared to 8 NON-GLP1 subjects treated with Skinvive for skin quality.
Experimental: NON GLP1 Patients
8 participants who are GLP1 naive will receive one treatment with microdroplet hyaluronic acid filler (SKINVIVE™, JUVÉDERM®, Irvine, CA) to the cheeks.
Device: Skinvive
16 GLP1 subjects treated with Skinvive to their cheeks for skin quality will be compared to 8 NON-GLP1 subjects treated with Skinvive for skin quality.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global Fine Lines
Time Frame: Screening, Day 30, Day 60
Score 0 no fine lines thru 9 numerous, many fine lines
Screening, Day 30, Day 60
Overall Hyperpigmentation
Time Frame: Screening, Day 30, Day 60
Score 0= no hyperpigmentation thru 9= significant hyperpigmentation
Screening, Day 30, Day 60
Skin Tone Evenness
Time Frame: Screening, Day 30, Day 60
Score 0= Very even tone thru Score 9= Uneven, discolored appearance (brown and/or red colors)
Screening, Day 30, Day 60
Skin Firmness
Time Frame: Screening, Day 30, Day 60
Score 0= Firm, tight feeling skin thru Score 9= Loose, lax feeling skin
Screening, Day 30, Day 60
Skin Radiance/ Brightness
Time Frame: Screening, Day 30, Day 60
Score 0= Very radiant, luminous or glowing appearance thru Score 9= Very dull/ matte and/or sallow skin appearance
Screening, Day 30, Day 60
Skin Texture Smoothness
Time Frame: Screening, Day 30, Day 60
Score 0= Very smooth, even-looking skin texture, no roughness thru Score 9= Very rough, pronounced, extensive visible skin roughness
Screening, Day 30, Day 60
Global Wrinkles
Time Frame: Screening, Day 30, Day 60
Score 0= No wrinkles present, no visible deep, wide and long wrinkles, skin looks smooth thru Score 9= Numerous wrinkles, deep, wide and long, densely packed together in the treatment area
Screening, Day 30, Day 60

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical Global Aesthetic Improvement Scale
Time Frame: Day 30 and Day 60

Assess improvement of Abdominal skin laxity:

Much Improved 2 Improved 1 No Change 0 Worse -1 Much Worse -2
Day 30 and Day 60
Subject Global Aesthetic Improvement Scale
Time Frame: Day 30 and Day 60

Assess improvement of Abdominal skin laxity:

Much Improved 2 Improved 1 No Change 0 Worse -1 Much Worse -2
Day 30 and Day 60

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Goldman, Butterwick, Fitzpatrick and Groff

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2025

Primary Completion (Estimated)

January 30, 2026

Study Completion (Estimated)

March 2, 2026

Study Registration Dates

First Submitted

October 24, 2025

First Submitted That Met QC Criteria

October 24, 2025

First Posted (Estimated)

October 28, 2025

Study Record Updates

Last Update Posted (Estimated)

October 28, 2025

Last Update Submitted That Met QC Criteria

October 24, 2025

Last Verified

October 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Skinvive GLP1 agonist

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Wrinkle

Clinical Trials on Skinvive

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe